CIPRIANI, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 6.332
EU - Europa 5.344
AS - Asia 1.567
OC - Oceania 14
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 10
SA - Sud America 8
Totale 13.287
Nazione #
US - Stati Uniti d'America 6.298
GB - Regno Unito 2.279
CN - Cina 1.184
IT - Italia 686
FR - Francia 565
FI - Finlandia 444
IE - Irlanda 385
DE - Germania 353
SE - Svezia 330
SG - Singapore 204
UA - Ucraina 148
VN - Vietnam 71
RU - Federazione Russa 48
TR - Turchia 29
JP - Giappone 27
NL - Olanda 27
CA - Canada 25
IL - Israele 19
BE - Belgio 16
RO - Romania 16
AU - Australia 14
EU - Europa 9
CH - Svizzera 8
MX - Messico 8
ES - Italia 7
AT - Austria 5
PL - Polonia 5
BR - Brasile 4
EG - Egitto 4
HU - Ungheria 4
IR - Iran 4
KR - Corea 4
SK - Slovacchia (Repubblica Slovacca) 4
AZ - Azerbaigian 3
GR - Grecia 3
SA - Arabia Saudita 3
ZA - Sudafrica 3
BG - Bulgaria 2
CL - Cile 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
ID - Indonesia 2
PH - Filippine 2
PK - Pakistan 2
SC - Seychelles 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BY - Bielorussia 1
DK - Danimarca 1
IN - India 1
IQ - Iraq 1
KE - Kenya 1
KH - Cambogia 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
TJ - Tagikistan 1
TW - Taiwan 1
Totale 13.287
Città #
Southend 2.103
Jacksonville 1.297
Woodbridge 967
Chandler 841
Ann Arbor 580
Houston 549
Dublin 385
Wilmington 222
Lawrence 216
Princeton 216
Beijing 202
Ashburn 165
Verona 148
Singapore 135
Nanjing 128
Jinan 109
New York 106
Shenyang 100
Milan 80
Hebei 73
Dong Ket 56
Sindelfingen 47
Changsha 45
Nanchang 45
Helsinki 44
Tianjin 44
Haikou 40
Ningbo 35
Rome 35
Hangzhou 34
Boardman 33
Washington 32
Norwalk 31
Dearborn 30
Redwood City 30
Taiyuan 29
Zhengzhou 28
Guangzhou 26
Jiaxing 25
Taizhou 24
Lancaster 20
Bologna 18
San Francisco 18
Tokyo 17
Toronto 17
Brussels 14
Fuzhou 14
Düsseldorf 13
Falls Church 13
Los Angeles 13
Lanzhou 12
London 11
Florence 10
Fairfield 9
Amsterdam 8
Seattle 8
Timisoara 8
Cagliari 7
Dongguan 7
Kent 7
Mexico City 7
Naples 7
Shanghai 7
Canberra 6
Groningen 6
Isorella 6
Auburn Hills 5
Melbourne 5
Trento 5
Zurich 5
Berlin 4
Brampton 4
Bratislava 4
Brescia 4
Frankfurt am Main 4
Manchester 4
Moscow 4
Padova 4
Redmond 4
Rochester 4
Saint Petersburg 4
San Diego 4
Seoul 4
Stockholm 4
Stuttgart 4
Tel Aviv 4
Villafranca Tirrena 4
Yicheng 4
Austin 3
Baku 3
Bergamo 3
Budapest 3
Cairo 3
Cambridge 3
Catania 3
Chicago 3
Clearwater 3
Genoa 3
Leipzig 3
Madrid 3
Totale 9.746
Nome #
Efficacia del litio nella depressione resistente con rischio suicidario. Studio indipendente, pragmatico, multicentrico, di superiorità 343
Efficacia del litio nella depressione resistente con rischio suicidario. Studio indipendente, pragmatico, multicentrico, di superiorità 306
[(123)I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. 153
Development of a registry for monitoring psychotropic drug prescriptions: Aims, methods and implications for ordinary practice and research 122
Trazodone nell'anziano con problemi di insonnia: quale il razionale? 114
Assessing risk of bias in randomized controlled trials 110
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial 109
[Randomized trials, systematic reviews, meta-analyses: basic criteria in the world of scientific evidence]. 108
What is a systematic review? 102
What is a run-in phase? 102
Associazione tra TCA e SSRI nella depressione resistente 100
Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials 99
Allocation concealment and blinding in clinical trials 93
Imputing missing standard deviations in meta-analyses can provide accurate results 91
What is a forest plot? 91
What is a risk ratio? 90
Agomelatine and the brave old world of narrative-based medicine 90
Understanding antipsychotic non-classical prescriptions: a quantitative and qualitative approach 88
An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios 87
Are all antidepressants really the same? The case of fluoxetine: a systematic review 86
Antidepressant drug prescription and risk of abnormal bleeding. A case-control study 86
Citalopram versus other anti-depressive agents for depression 86
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia 86
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial 85
Trasformare la pratica clinica in ricerca. Un invito a partecipare allo studio CHAT 84
Antidepressants and benzodiazepines for panic disorder in adults 84
Seven criteria for improving effectiveness trials in psychiatry 83
Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone 83
Beneficial and adverse effects of antidepressants on suicide mortality in individuals with major depression 83
Forensic database study suggests selective serotonin reuptake inhibitors do not increase the risk of suicide in people taking antidepressants 82
Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial 82
Effect of antipsychotic drugs on cerebrovascular morbidity and mortality: a systematic review 81
Sertraline versus other antidepressive agents for depression 81
Randomized trials published in Chinese or Western journals: comparative empirical analysis 81
Antidepressive Monotherapie 80
Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review 80
Citalopram versus other anti-depressive agents for depression 78
Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials 78
Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies 77
Duloxetine versus other anti-depressive agents for depression 77
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis 77
Depressive disorders 76
Conventional vs. atypical antipsychotic medications [Letter] 75
Paroxetine versus other anti-depressive agents for depression 75
Azapirones versus placebo for panic disorder in adults 75
Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: a protocol for a randomised, independent, pragmatic, multicentre, parallel-group, superiority clinical trial 75
Comparative efficacy and acceptability of antimanic drugsin acute mania: a multiple-treatments meta-analysis 74
Commentary on: Analysis and reporting of factorial trials: a systematic review (McAlister et al., JAMA) 73
Implementation of treatment guidelines for specialist mental health care 73
What is a clinical trial protocol? 72
Benzodiazepines and risk of dementia: true association or reverse causation? 72
Dalle revisioni narrative a quelle sitematiche e alle metanalisi, per un approccio moderno alla valutazione dei trattamenti farmacologici in psichiatria 71
Fluoxetine versus other types of pharmacotherapy for depression (Review) 71
Risk of suicidal behaviour in adults taking antidepressants 71
Adherence therapy does not improve quality of life in people with schizophrenia [Comment] 71
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis 71
Mirtazapine versus other antidepressive agents for depression 71
Do selective serotonin reuptake inhibitors cause suicide? Authors' reply to Raven 70
Antidepressants and suicide symptoms: compelling new insights from the FDA's analysis of individual patient level data 70
Citalopram versus other anti-depressive agents for depression. 70
Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. 70
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis 70
Fluoxetine versus other types of pharmacotherapy for depression (Protocol for a Cochrane Review) 69
"Wish bias" in antidepressant drug trials? 69
Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy 69
Understanding and using systematic literature reviews 69
Implementation of treatment guidelines for specialist mental health care 69
Comparison of systematic and narrative reviews: the example of the atypical antipsychotics 68
Outcome reporting bias in clinical trials 68
What is an intention to treat analysis? 68
Psychological therapies versus pharmacotherapy for obsessive compulsive disorder (Protocol) 68
Trasformare la pratica clinica in ricerca. Un invito a partecipareallo studio CHAT. 68
What is a multiple treatments meta-analysis? 68
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis 68
Suicide, depression, and antidepressants. Patients and clinicians need to balance benefits and harms 67
Olanzapine in long-term treatment for bipolar disorder. 67
Review: Short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs. 67
Inglobare la ricerca nella pratica clinica quotidiana 66
Validity of the impact factor of journals as a measure of randomised controlled trial quality 65
Why internal and external validity of experimental studies are relevant for clinical practice? 65
Haloperidol alone or in combination for acute mania 64
Antidepressants for Bipolar Disorder 64
Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials 63
What is an individual patient data meta-analysis? 63
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. 63
Does the addiction of a second antipsychotic drug improve clozapine treatment? 62
What is a randomised controlled trial? 62
Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis 62
Cognitive improvements with antipsychotics: Real or practice effect? - Commentary 61
Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis 61
Explanatory and pragmatic trials 60
Levels of evidence: can quality of systematic reviews be quantified? 60
Aripiprazole in addition to clozapine in partially responsive patients with schizophrenia: a critical review of case series 60
Novel melatonin-based treatments for major depression 60
What is a factorial trial? 60
Implementation of treatment guidelines for specialist mental health care 60
Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis 59
Fluoxetine versus other types of pharmacotherapy for depression 59
Sertraline versus other antidepressive agents for depression 59
Imputing response rates from means and standard deviations in meta-analyses 58
Totale 8.152
Categoria #
all - tutte 43.045
article - articoli 40.229
book - libri 199
conference - conferenze 0
curatela - curatele 0
other - altro 1.234
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.383
Totale 86.090


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.724 272 14 9 184 99 208 258 170 60 202 73 175
2020/20211.547 91 310 45 134 226 192 18 147 127 23 137 97
2021/20221.254 72 282 25 57 42 29 12 91 60 31 140 413
2022/20232.732 253 166 332 431 290 572 33 183 320 30 70 52
2023/20241.351 71 129 111 118 162 187 47 92 19 83 190 142
2024/202517 17 0 0 0 0 0 0 0 0 0 0 0
Totale 13.415